MediPharm Labs Report sees Quarterly Revenue Drop 25%

This morning MediPharm Labs (TSX: LABS) released their fourth quarter results for the year ended December 31, 2019. The quarter saw revenues decline approximately 25.4% from the previous quarter with a 73.6% decline in Adjusted EBITDA over the same period.

The previously beloved cannabis market darling saw a decline in pretty much everything on a quarterly basis:

Q4 2019Q3 2019% Change
Cash $  38,627  $   42,116 -8.3%
Inventory $  51,486  $   54,086 -4.8%
Receivables $  27,540  $   40,756 -32.4%
Accounts Payable $  20,946  $   41,704 -49.8%
Revenue $  32,444  $   43,486 -25.4%
Gross Profit $    9,987  $   14,754 -32.3%
Net Income (pre Tax) $  (2,401) $      5,395 -144.5%
Adjusted EBITDA $    2,661  $   10,066 -73.6%
Operating Cash Flow $  14,100  $   17,069 -17.4%
Investing Cash Flow $  (2,182) $ (10,799)-79.8%

The company cited oversupply of bulk extract, reduction in selling price, lower volumes, slower rollout of cannabis 2.0, slower rollout of retail and lastly a slower rollout of bigger companies entering the space.


The Company reported that the Canadian cannabis sector experienced significant challenges in the fourth quarter that resulted in an oversupply of bulk extract in the market and subsequent reduction in selling price and lower volumes. These factors included: a slower than anticipated expansion of retail channels in Canada, slower licensing of new and specialized cannabis 2.0 businesses, lower than expected conversion of bulk extract inventory into finished goods by vertically integrated players and slower than expected entry to the market by larger consumer packaged goods and pharmaceutical companies.


The company informed shareholders the manufacturing facility was exempted from the recent provincial mandated workplace closures as an essential service. But the company sees some issues with the supply chain potentially breaking down.

At the time of publishing MedipPharm Labs is down 14.65% to $1.69.


Information for this briefing was found via Sedar and MediPharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Canaccord Genuity Raises Medipharm Labs’ Price Target To C$2.50

On Monday Medipharm Labs (TSX: LABS) announced an exclusive medical cannabis partnership with the European...

Tuesday, October 6, 2020, 01:29:18 PM

Medipharm Labs Reports Revenues of $31 million for Second Quarter

Medipharm Labs (TSX: LABS) filed its second quarter earnings after the bell this evening, reporting...

Monday, August 12, 2019, 05:35:41 PM

Canaccord: 2020 To Be Transition Year For Medipharm Labs

Last week, Medipharm Labs (TSX: LABS) reported their second-quarter earnings. Revenue came in at $13.9...

Saturday, August 22, 2020, 01:38:00 PM

Medipharm Labs Appoints Former Purdue Pharma Exec As CEO

Medipharm Labs (TSX: LABS) continues to suffer from management turnover. The company today announced that...

Wednesday, April 20, 2022, 07:56:47 AM

Medipharm Labs Announces White Label Agreement, Provides No Details

Medipharm Labs (TSX: LABS) has entered into its second white label supply agreement with its...

Monday, May 4, 2020, 08:24:41 AM